AU594014B2
(en)
*
|
1984-03-21 |
1990-03-01 |
Research Corporation Technologies, Inc. |
Recombinant DNA molecules
|
US5718893A
(en)
*
|
1984-04-15 |
1998-02-17 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
DE3680613D1
(de)
*
|
1985-02-08 |
1991-09-05 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
|
US5532341A
(en)
*
|
1985-03-28 |
1996-07-02 |
Sloan-Kettering Institute For Cancer Research |
Human pluripotent hematopoietic colony stimulating factor
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US6004548A
(en)
*
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
NZ218336A
(en)
*
|
1985-12-09 |
1991-08-27 |
Kirin Amgen Inc |
Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
|
DK203187A
(da)
*
|
1986-04-22 |
1987-10-23 |
Immunex Corp |
Human g-csf proteinekspression
|
GR871067B
(en)
*
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
US5186931A
(en)
*
|
1986-08-06 |
1993-02-16 |
Ajinomoto Co., Inc. |
Composition and method for supporting bone marrow transplantation
|
AU7675487A
(en)
*
|
1986-08-11 |
1988-05-19 |
Cetus Corporation |
Expression of granulocyte colony-stimulating factor
|
JPH0618781B2
(ja)
*
|
1986-10-18 |
1994-03-16 |
中外製薬株式会社 |
感染症治療剤
|
US6238889B1
(en)
*
|
1986-12-16 |
2001-05-29 |
Dsm N.V. |
Molecular cloning and expression of the Pro8 isoform of human IL-3
|
DK174044B1
(da)
|
1986-12-23 |
2002-05-06 |
Kyowa Hakko Kogyo Kk |
Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
|
JP2618618B2
(ja)
*
|
1988-03-04 |
1997-06-11 |
協和醗酵工業株式会社 |
抗g−csf誘導体、nd28モノクローナル抗体
|
US5681720A
(en)
*
|
1986-12-23 |
1997-10-28 |
Kyowa Hakko Co., Ltd. |
DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
|
US5214132A
(en)
*
|
1986-12-23 |
1993-05-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
US5362853A
(en)
*
|
1986-12-23 |
1994-11-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
US5194592A
(en)
*
|
1986-12-23 |
1993-03-16 |
Kyowa Hakko Kogyo Co. Ltd. |
Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
|
US6384194B1
(en)
*
|
1987-12-16 |
2002-05-07 |
Dsm N.V. |
Expression and purification of human interleukin-3 and muteins thereof
|
GB2213821B
(en)
*
|
1987-12-23 |
1992-01-02 |
British Bio Technology |
Synthetic human granulocyte colony stimulating factor gene
|
US5599690A
(en)
*
|
1988-02-01 |
1997-02-04 |
Amgen Inc. |
Control of norleucine incorporation into recombinant proteins
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
KR0133561B1
(ko)
*
|
1988-05-13 |
1998-04-21 |
스티븐 엠. 오드레 |
과립구 군체 자극인자의 정제방법
|
US5070013A
(en)
*
|
1988-05-31 |
1991-12-03 |
Schering Corporation |
Immunochemical assay for human granulocyte-macrophage colony stimulating factor
|
US5082774A
(en)
*
|
1988-08-30 |
1992-01-21 |
The General Hospital Corporation |
Recombinant human nerve growth factor
|
US5218092A
(en)
*
|
1988-09-29 |
1993-06-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
|
US5104651A
(en)
*
|
1988-12-16 |
1992-04-14 |
Amgen Inc. |
Stabilized hydrophobic protein formulations of g-csf
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
JP2989002B2
(ja)
*
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
AU5355790A
(en)
*
|
1989-04-19 |
1990-11-16 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6254861B1
(en)
*
|
1989-05-23 |
2001-07-03 |
Chandra Choudhury |
Hematopoietic growth factor derived from T lymphocytes
|
US5605822A
(en)
*
|
1989-06-15 |
1997-02-25 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for growing human hematopoietic cells
|
WO1990015877A2
(en)
*
|
1989-06-15 |
1990-12-27 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for growing cells
|
US5763266A
(en)
*
|
1989-06-15 |
1998-06-09 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
|
US5635386A
(en)
*
|
1989-06-15 |
1997-06-03 |
The Regents Of The University Of Michigan |
Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
US5665543A
(en)
*
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
WO1991005798A1
(en)
*
|
1989-10-10 |
1991-05-02 |
Amgen Inc. |
Compositions and methods for treating or preventing infections in canine and feline animals
|
CA2025181A1
(en)
*
|
1989-10-12 |
1991-04-13 |
William G. Weisburg |
Nucleic acid probes and methods for detecting fungi
|
ZA907921B
(en)
|
1989-10-16 |
1991-08-28 |
Amgen Inc |
Stem cell factor
|
SG43009A1
(en)
*
|
1989-10-16 |
1997-10-17 |
Amgen Inc |
Stem cell factor
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
US7144731B2
(en)
*
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
AU6541090A
(en)
*
|
1989-10-16 |
1991-05-16 |
Amgen, Inc. |
Stem cell factor
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US5214133A
(en)
*
|
1989-11-17 |
1993-05-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SCL: a hematopoietic growth and differentiation factor
|
US5132212A
(en)
*
|
1989-11-17 |
1992-07-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
US5147799A
(en)
*
|
1990-04-25 |
1992-09-15 |
Isia Bursuker |
Repopulation of macrophages and granulocytes using transforming growth factor-beta
|
GB9107846D0
(en)
*
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
US5399345A
(en)
*
|
1990-05-08 |
1995-03-21 |
Boehringer Mannheim, Gmbh |
Muteins of the granulocyte colony stimulating factor
|
US5258367A
(en)
*
|
1990-06-29 |
1993-11-02 |
University Of Florida |
Uteroferrin and rose proteins for stimulating hematopoietic cells
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
AU1462392A
(en)
*
|
1991-02-22 |
1992-09-15 |
Amgen, Inc. |
Use of gm-csf and g-csf to promote accelerated wound healing
|
DE69233336T2
(de)
*
|
1991-02-26 |
2005-03-31 |
Astrazeneca Ab |
Vektor
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5738849A
(en)
*
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
US5772992A
(en)
*
|
1992-11-24 |
1998-06-30 |
G.D. Searle & Co. |
Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
|
US6361977B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Methods of using multivariant IL-3 hematopoiesis fusion protein
|
US7091319B1
(en)
|
1992-11-24 |
2006-08-15 |
Bauer S Christopher |
IL-3 variant hematopoiesis fusion protein
|
US6413509B1
(en)
|
1992-11-24 |
2002-07-02 |
S. Christopher Bauer |
Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
|
US6153183A
(en)
*
|
1992-11-24 |
2000-11-28 |
G. D. Searle & Company |
Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
|
US6361976B1
(en)
*
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
|
US6403076B1
(en)
|
1992-11-24 |
2002-06-11 |
S. Christopher Bauer |
Compositions for increasing hematopoiesis with interleukin-3 mutants
|
US6057133A
(en)
*
|
1992-11-24 |
2000-05-02 |
G. D. Searle |
Multivariant human IL-3 fusion proteins and their recombinant production
|
AU2007200247B2
(en)
*
|
1993-01-28 |
2011-03-10 |
Amgen Inc. |
G-CSF analog compositions
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
ATE440957T1
(de)
|
1993-09-15 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
Rekombinante alphavirus vektoren
|
US5874075A
(en)
*
|
1993-10-06 |
1999-02-23 |
Amgen Inc. |
Stable protein: phospholipid compositions and methods
|
US20050059149A1
(en)
*
|
1993-11-22 |
2005-03-17 |
Bauer S. Christopher |
Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
|
CA2139385C
(en)
*
|
1994-02-04 |
2001-12-25 |
Gottfried Alber |
Products containing g-csf and tnf binding protein
|
US6242417B1
(en)
|
1994-03-08 |
2001-06-05 |
Somatogen, Inc. |
Stabilized compositions containing hemoglobin
|
US5631219A
(en)
*
|
1994-03-08 |
1997-05-20 |
Somatogen, Inc. |
Method of stimulating hematopoiesis with hemoglobin
|
EP0690127B1
(de)
*
|
1994-03-31 |
1998-08-05 |
Amgen Inc. |
Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
US5536495A
(en)
*
|
1994-04-15 |
1996-07-16 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US6066318A
(en)
|
1995-10-05 |
2000-05-23 |
G.D. Searle & Co. |
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
|
US6100070A
(en)
*
|
1995-10-05 |
2000-08-08 |
G. D. Searle & Co. |
G-CSF receptor agonists
|
JP4383530B2
(ja)
|
1996-04-05 |
2009-12-16 |
ノバルティス バクシンズ アンド ダイアグノスティックス, インコーポレーテッド |
細胞巨大分子合成の阻害が減少したアルファウイルスベクター
|
EP2298900A1
(de)
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
|
US6162426A
(en)
*
|
1997-05-05 |
2000-12-19 |
La Gamma; Edmund F. |
Use of G-CSF to enhance the immune system in neonates
|
US7153943B2
(en)
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
EP1881005B1
(de)
*
|
1997-07-14 |
2013-04-03 |
Bolder Biotechnology, Inc. |
Derivate von G-CSF und damit zusammenhängende Proteine
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
ES2221212T5
(es)
*
|
1997-10-02 |
2008-12-01 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes.
|
US20020034819A1
(en)
*
|
1998-02-23 |
2002-03-21 |
Alan K. Smith |
Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
CN1101403C
(zh)
*
|
1998-07-13 |
2003-02-12 |
金磊 |
粒细胞集落刺激因子的制备
|
US6979442B1
(en)
|
1998-08-17 |
2005-12-27 |
Pfizer Inc. |
Stabilized protein compositions
|
US5999474A
(en)
|
1998-10-01 |
1999-12-07 |
Monolithic System Tech Inc |
Method and apparatus for complete hiding of the refresh of a semiconductor memory
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US6602705B1
(en)
|
1998-12-31 |
2003-08-05 |
Chiron Corporation |
Expression of HIV polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
AU770131B2
(en)
|
1999-01-06 |
2004-02-12 |
Xencor, Inc. |
Nucleic acids and proteins corresponding to mutants of G-CSF with granulopoietic activity
|
US7208473B2
(en)
*
|
1999-01-06 |
2007-04-24 |
Xencor, Inc. |
Nucleic acids and protein variants of hG-CSF with granulopoietic activity
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
DE60041386D1
(de)
|
1999-01-19 |
2009-03-05 |
Molecular Insight Pharm Inc |
Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen
|
ATE246202T1
(de)
*
|
1999-01-29 |
2003-08-15 |
Hoffmann La Roche |
Gcsf konjugate
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
KR100356140B1
(ko)
*
|
1999-07-08 |
2002-10-19 |
한미약품공업 주식회사 |
인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
JP5099951B2
(ja)
|
1999-11-12 |
2012-12-19 |
バクスター・インターナショナル・インコーポレイテッド |
副作用が減少されたヘモグロビン組成物
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
WO2001051510A2
(en)
|
2000-01-10 |
2001-07-19 |
Maxygen Holdings Ltd |
G-csf conjugates
|
ES2220673T3
(es)
|
2000-02-29 |
2004-12-16 |
Pfizer Products Inc. |
Factor estimulante de colonias de granulocitos estabilizado.
|
NZ521937A
(en)
*
|
2000-03-31 |
2004-08-27 |
Celgene Corp |
Inhibition of cyclooxygenase-2 activity
|
AU2001264563A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US8435939B2
(en)
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
CA2421757A1
(en)
|
2000-09-08 |
2002-03-14 |
Massachusetts Institute Of Technology |
G-csf analog compositions and methods
|
EP1195437A1
(de)
*
|
2000-10-04 |
2002-04-10 |
Mitsui Chemicals, Inc. |
Verfahren zur rekombinanten Herstellung von Proteine durch Verwendung eines Plac/Np Hybrid-Promotor
|
CA2430669C
(en)
*
|
2000-11-30 |
2011-06-14 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
EP1229045A1
(de)
|
2001-02-01 |
2002-08-07 |
Institut Curie |
Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
|
CN100404673C
(zh)
|
2001-02-19 |
2008-07-23 |
默克专利有限公司 |
鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
|
FR2820979B1
(fr)
|
2001-02-22 |
2004-03-12 |
Didier Pourquier |
Nouvelle application therapeutique du g-csf
|
US6956023B1
(en)
|
2001-04-19 |
2005-10-18 |
University Of Florida |
Materials and methods for providing nutrition to neonates
|
EP2280074A3
(de)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
DE60236522D1
(de)
|
2001-07-11 |
2010-07-08 |
Maxygen Inc |
G-csf konjugate
|
RU2309741C2
(ru)
*
|
2001-07-31 |
2007-11-10 |
Анормед Инк. |
Способы активации клеток-предшественников/стволовых клеток
|
US7169750B2
(en)
*
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
EP2042196B1
(de)
|
2001-10-10 |
2016-07-13 |
ratiopharm GmbH |
Neumodellierung und Glykokonjugation von Granulozyten-Kolonie stimulierender Faktor (G-CSF)
|
EP2322229B1
(de)
|
2001-10-10 |
2016-12-21 |
Novo Nordisk A/S |
Neumodulierung und Glykokonjugation von Faktor IX
|
SI21102A
(sl)
|
2001-12-19 |
2003-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
|
EP1997829A1
(de)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
KR20030062854A
(ko)
*
|
2002-01-21 |
2003-07-28 |
주식회사 엘지생명과학 |
분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
|
WO2003078461A1
(en)
*
|
2002-03-20 |
2003-09-25 |
Biopolymed Inc. |
Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
EP2339010B1
(de)
|
2002-05-01 |
2017-04-12 |
Miltenyi Biotec Technology, Inc. |
Gegenüber Komplement-Inaktivierung resistente Lentivirusvektorpartikel
|
MXPA04011310A
(es)
|
2002-05-17 |
2005-02-14 |
Celgene Corp |
Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
IL165254A0
(en)
|
2002-05-17 |
2005-12-18 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7081443B2
(en)
*
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
WO2004001056A1
(en)
*
|
2002-06-24 |
2003-12-31 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing g-csf
|
SI21273A
(sl)
*
|
2002-07-31 |
2004-02-29 |
LEK farmacevtska dru�ba d.d. |
Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
|
WO2004020462A1
(ja)
|
2002-08-27 |
2004-03-11 |
Fujii, Nobutaka |
Cxcr4拮抗薬およびその用途
|
CA2498319A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
MXPA05003889A
(es)
*
|
2002-10-15 |
2005-06-22 |
Celgene Corp |
Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
ZA200503655B
(en)
|
2002-11-06 |
2006-08-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
KR20100125479A
(ko)
*
|
2002-11-26 |
2010-11-30 |
안트로제네시스 코포레이션 |
세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
|
US7695723B2
(en)
|
2002-12-31 |
2010-04-13 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
WO2004058287A2
(en)
*
|
2002-12-31 |
2004-07-15 |
Axaron Bioscience Ag |
Methods of treating neurological conditions with hematopoeitic growth factors
|
US7785601B2
(en)
*
|
2002-12-31 |
2010-08-31 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
US20040219136A1
(en)
*
|
2003-02-13 |
2004-11-04 |
Hariri Robert J |
Use of umbilical cord blood to treat individuals having a disease, disorder or condition
|
AU2004220457A1
(en)
|
2003-03-12 |
2004-09-23 |
Celgene Corporation |
7-amino- isoindolyl compounds amd their pharmaceutical uses
|
SG155777A1
(en)
|
2003-04-09 |
2009-10-29 |
Neose Technologies Inc |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
NZ542850A
(en)
|
2003-04-22 |
2007-12-21 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
US20070041937A1
(en)
*
|
2003-08-22 |
2007-02-22 |
The Council Of The Queensland Institute Of Medical Research |
G-csf derivative for inducing immunological tolerance
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
ZA200603718B
(en)
*
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
AU2004296765B2
(en)
*
|
2003-12-02 |
2011-03-24 |
Celgene Corporation |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20060003008A1
(en)
|
2003-12-30 |
2006-01-05 |
Gibson John W |
Polymeric devices for controlled release of active agents
|
EP1718664A4
(de)
|
2004-02-02 |
2008-08-13 |
Ambrx Inc |
Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
|
SE0400942D0
(sv)
*
|
2004-04-08 |
2004-04-08 |
Henrik Arnberg |
Composition and method
|
JP2007532642A
(ja)
*
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
|
CA2562715A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
EP1586334A1
(de)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF Konjugate mit PEG
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
MX2007001589A
(es)
*
|
2004-08-09 |
2007-08-02 |
Alios Biopharma Inc |
Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
|
US20060035829A1
(en)
*
|
2004-08-13 |
2006-02-16 |
Anormed Inc. |
Chemokine combinations to mobilize progenitor/stem cells
|
CA2621250A1
(en)
*
|
2004-09-07 |
2006-03-16 |
Zymequest, Inc. |
Apparatus for prolonging survival of platelets
|
EP1819355A4
(de)
|
2004-09-28 |
2009-08-12 |
Genexel Sein Inc |
Verfahren zur verwendung eines chimärischen coiled-coil-moleküls
|
GB0505353D0
(en)
|
2005-03-16 |
2005-04-20 |
Chem Technologies Ltd E |
Treatment process for concrete
|
WO2006050394A2
(en)
|
2004-11-01 |
2006-05-11 |
Novartis Vaccines And Diagnostics Inc. |
Combination approaches for generating immune responses
|
AU2005306894B2
(en)
|
2004-11-05 |
2011-11-24 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
WO2006067170A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Laboratoires Serono S.A. |
G-csf polypeptides and uses thereof
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
JP5735194B2
(ja)
|
2005-01-25 |
2015-06-17 |
セル セラピューティクス インコーポレーテッド |
改善された生体内半減期を有する生物学的に活性なタンパク質
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
EP1888119B1
(de)
*
|
2005-06-01 |
2011-03-09 |
Maxygen, Inc. |
Pegylierte g-csf-polypeptide und herstellungsverfahren dafür
|
EP1739179A1
(de)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
|
DE102005033250A1
(de)
†
|
2005-07-15 |
2007-01-18 |
Bioceuticals Arzneimittel Ag |
Verfahren zur Reinigung von G-CSF
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
WO2007019331A2
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics Al, Corporation |
Conjugates of a g-csf moiety and a polymer
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
EP1954304A4
(de)
*
|
2005-10-14 |
2010-03-10 |
Zymequest Inc |
Zusammensetzungen und verfahren zur verlängerung der lebensdauer von plättchen
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
AU2006340074A1
(en)
*
|
2006-02-24 |
2007-09-20 |
Genzyme Corporation |
Methods for increasing blood flow and/or promoting tissue regeneration
|
DE202006020194U1
(de)
|
2006-03-01 |
2007-12-06 |
Bioceuticals Arzneimittel Ag |
G-CSF-Flüssigformulierung
|
WO2007102814A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Regenetech, Inc. |
Recombinant mammalian molecules and method for production thereof
|
GB0605684D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Sicor Biotech Uab |
Method For Purifying Granulocyte-Colony Stimulating Factor
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
EP2043645A2
(de)
|
2006-06-12 |
2009-04-08 |
Sunesis Pharmaceuticals, Inc. |
Verbindungen und zusammensetzungen zur behandlung von krebs
|
EP3025712A1
(de)
*
|
2006-08-02 |
2016-06-01 |
Sunesis Pharmaceuticals, Inc. |
Kombinierte verwendung von (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carboxylsäure und cytarabin (ara-c) zur behandlung von leukämie
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
EP2056853A1
(de)
*
|
2006-08-07 |
2009-05-13 |
Genzyme Corporation |
Kombinationstherapie
|
US8663651B2
(en)
|
2006-12-21 |
2014-03-04 |
Biokine Therapeutics Ltd. |
T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
|
WO2008096370A2
(en)
*
|
2007-02-05 |
2008-08-14 |
Natco Pharma Limited |
An efficient and novel purification method of recombinant hg-csf
|
US8114630B2
(en)
*
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CN101801942B
(zh)
*
|
2007-07-17 |
2013-03-27 |
美国艾森生物科学公司 |
杂环化合物和作为抗癌剂的用途
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
EP2185689A2
(de)
|
2007-08-09 |
2010-05-19 |
Genzyme Corporation |
Verfahren zur behandlung von autoimmunerkrankungen mit mesenchymalen stammzellen
|
PT2197919E
(pt)
|
2007-08-27 |
2014-07-17 |
Ratiopharm Gmbh |
Formulação líquida de conjugado de g-csf
|
AU2008291309B2
(en)
|
2007-08-27 |
2013-10-17 |
Ratiopharm Gmbh |
Liquid formulation of G-CSF
|
US8758761B2
(en)
*
|
2007-09-30 |
2014-06-24 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
KR100921226B1
(ko)
|
2007-10-04 |
2009-10-12 |
학교법인 선목학원 |
사람 혈액의 과립구집락자극인자(hG-CSF) 유전자를 내장하는 레트로바이러스 발현벡터 및 이에 의해 형질전환된 가금
|
EP2214824A4
(de)
*
|
2007-11-28 |
2015-08-19 |
Smart Tube Inc |
Vorrichtungen, systeme und verfahren zur entnahme, stimulation, stabilisierung und analyse einer biologischen probe
|
WO2009075841A2
(en)
|
2007-12-10 |
2009-06-18 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
EP2247743B1
(de)
|
2008-02-08 |
2016-04-06 |
Ambrx, Inc. |
Modifizierte leptin-polypeptide und deren verwendungen
|
US20100113341A1
(en)
*
|
2008-04-30 |
2010-05-06 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
DK2695609T3
(da)
|
2008-05-15 |
2020-02-10 |
Celgene Corp |
Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
|
MX2011000859A
(es)
*
|
2008-07-23 |
2011-02-24 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados y sus usos.
|
EP2396023A2
(de)
|
2009-02-11 |
2011-12-21 |
Yeda Research and Development Co. Ltd. |
Kurze peptide aus beta-defensin
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
ES2462517T3
(es)
|
2009-06-14 |
2014-05-23 |
Biokine Therapeutics Ltd. |
Terapia con péptidos para aumentar los niveles de plaquetas
|
EA020621B1
(ru)
|
2009-06-22 |
2014-12-30 |
Амген Инк. |
Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
|
KR20120124353A
(ko)
|
2009-06-24 |
2012-11-13 |
스티븐 에반스-프레케 |
암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법
|
JP2012531428A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
US20110129858A1
(en)
*
|
2009-11-27 |
2011-06-02 |
Changhua Christian Hospital |
Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
RS53010B
(en)
|
2009-12-31 |
2014-04-30 |
Arven Ilac Sanayi Ve Ticaret A.S. |
NEW PROCEDURE FOR PREPARATION OF G-CSF (GRANULOCITE COLONY STIMULATION FACTOR)
|
WO2011103509A1
(en)
|
2010-02-19 |
2011-08-25 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents
|
NZ602255A
(en)
*
|
2010-03-04 |
2014-04-30 |
Pfenex Inc |
Method for producing soluble recombinant interferon protein without denaturing
|
MX2012010367A
(es)
|
2010-03-12 |
2012-11-23 |
Celgene Corp |
Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
|
NZ603033A
(en)
|
2010-04-01 |
2014-06-27 |
Pfenex Inc |
Methods for g-csf production in a pseudomonas host cell
|
WO2012019168A2
(en)
*
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
BR112013007385B1
(pt)
|
2010-09-28 |
2022-07-26 |
Amylin Pharmaceuticals, Llc |
Polipeptídeo quimérico, seu uso e composição que o compreende
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
BR112013023279A2
(pt)
|
2011-03-11 |
2016-12-20 |
Celgene Corp |
formas sólidas de 3-(-5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona e suas composições farmacêuticas e usos
|
SI2683384T1
(sl)
|
2011-03-11 |
2016-05-31 |
Celgene Corporation |
Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
US9320777B2
(en)
|
2011-05-13 |
2016-04-26 |
Bolder Biotechnology, Inc. |
Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
|
WO2013063287A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
TW201700103A
(zh)
|
2011-11-01 |
2017-01-01 |
西建公司 |
利用胞嘧啶核苷類似物之口服配方治療癌症的方法
|
US8889630B2
(en)
|
2011-12-23 |
2014-11-18 |
Carlos Lopez |
Method for hair regrowth using Granulocyte-Colony Stimulating Factor
|
HUP1200172A2
(en)
*
|
2012-03-19 |
2013-10-28 |
Richter Gedeon Nyrt |
Methods for refolding g-csf from inclusion bodies
|
HUP1200171A1
(hu)
|
2012-03-19 |
2013-09-30 |
Richter Gedeon Nyrt |
Módszerek polipeptidek elõállítására
|
ES2681050T3
(es)
|
2012-04-11 |
2018-09-11 |
Acerta Pharma B.V. |
Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética
|
WO2013160895A1
(en)
|
2012-04-24 |
2013-10-31 |
Biokine Therapeutics Ltd. |
Peptides and use thereof in the treatment of large cell lung cancer
|
ES2699810T3
(es)
|
2012-06-29 |
2019-02-12 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
|
EP2870238A4
(de)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen
|
EP2879710B1
(de)
|
2012-08-03 |
2019-11-13 |
Dana-Farber Cancer Institute, Inc. |
Medizinische verwendungen von immunzellenaktivierungsmodulierenden substanzen und entsprechende screeningverfahren
|
JP6347782B2
(ja)
|
2012-08-09 |
2018-06-27 |
セルジーン コーポレイション |
3−(4−((4−(モルホリノメチル)ベンジル)オキシ)−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンを使用する癌の治療方法
|
ES2885769T3
(es)
|
2012-08-09 |
2021-12-15 |
Celgene Corp |
Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
EP2892537A1
(de)
|
2012-09-10 |
2015-07-15 |
Celgene Corporation |
Verfahren zur behandlung von lokal fortgeschrittenem brustkrebs
|
US9968627B2
(en)
|
2013-03-26 |
2018-05-15 |
Celgene Corporation |
Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
|
MX2015013912A
(es)
|
2013-04-02 |
2016-08-12 |
Celgene Corp |
Metodos y composiciones que utilizan 4-amino-2-(2,6-dioxo-piperidi n-3-il)-isoindolin-1,3-diona para tratamiento y manejo de canceres en el sistema nervioso central.
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
WO2015073727A1
(en)
|
2013-11-13 |
2015-05-21 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
US10034872B2
(en)
|
2014-08-22 |
2018-07-31 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
MA40517A
(fr)
|
2015-03-16 |
2016-09-21 |
Arven Ilac Sanayi Ve Ticaret As |
Procédé pour préparation du facteur stimulant les colonies de granulocytes (g-csf)
|
US20180118799A1
(en)
|
2015-04-13 |
2018-05-03 |
National Institute Of Advanced Industrial Science And Technology |
Cyclized cytokine and method for producing same
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
EP3744340A3
(de)
|
2015-07-16 |
2021-03-03 |
Biokine Therapeutics Ltd. |
Zusammensetzungen und verfahren zur behandlung von krebs
|
CN108348593B
(zh)
|
2015-08-31 |
2022-08-16 |
泰克诺瓦克斯股份有限公司 |
基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
|
US11229683B2
(en)
|
2015-09-18 |
2022-01-25 |
Bolder Biotechnology, Inc. |
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
WO2017067958A1
(en)
*
|
2015-10-19 |
2017-04-27 |
Sandoz Ag |
Improved coding sequence for human g-csf
|
EP3365359A1
(de)
|
2015-10-19 |
2018-08-29 |
Sandoz AG |
Verfahren zur herstellung eines rekombinanten proteins mit verminderten verunreinigungen
|
JP6864296B2
(ja)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
HUE060517T2
(hu)
|
2015-12-22 |
2023-03-28 |
X4 Pharmaceuticals Inc |
Immunhiányos betegség kezelésére szolgáló eljárások
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
ES2957477T3
(es)
|
2016-01-08 |
2024-01-19 |
Celgene Corp |
Compuestos antiproliferativos para usar en el tratamiento de leucemia
|
EP4275707A3
(de)
|
2016-01-08 |
2023-12-20 |
Celgene Corporation |
Formulierungen von 2-(4-chlorphenyl)-n-((2- (2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoracetamid
|
US10993985B2
(en)
|
2016-02-23 |
2021-05-04 |
BioLmeRx Ltd. |
Methods of treating acute myeloid leukemia
|
AU2017238054B2
(en)
|
2016-03-21 |
2023-10-19 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
BR112018070163A2
(pt)
|
2016-04-01 |
2019-01-29 |
Signal Pharm Llc |
compostos de aminopurina substituída, composições e métodos de tratamento
|
ES2895419T3
(es)
|
2016-04-01 |
2022-02-21 |
Signal Pharm Llc |
Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso
|
CN109153722A
(zh)
|
2016-04-08 |
2019-01-04 |
X4 制药有限公司 |
用于治疗癌症的方法
|
MX2018012376A
(es)
|
2016-04-13 |
2019-08-01 |
Synthetic Genomics Inc |
Sistemas de replicón de arterivirus recombinantes y usos de estos.
|
EP3471726A4
(de)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4-inhibitoren und verwendungen davon
|
EP3472129A4
(de)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
Cxcr4-inhibitoren und verwendungen davon
|
US10759796B2
(en)
|
2016-06-21 |
2020-09-01 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
JP7382230B2
(ja)
|
2016-10-17 |
2023-11-16 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
組み換えウイルスレプリコン系及びその使用
|
WO2018106615A2
(en)
|
2016-12-05 |
2018-06-14 |
Synthetic Genomics, Inc. |
Compositions and methods for enhancing gene expression
|
US20180258064A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
IL271230B1
(en)
|
2017-06-21 |
2024-02-01 |
SHY Therapeutics LLC |
Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
|
RS64029B1
(sr)
|
2017-06-30 |
2023-03-31 |
Celgene Corp |
Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida
|
WO2019070827A1
(en)
|
2017-10-04 |
2019-04-11 |
Celgene Corporation |
PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
|
JP7287955B2
(ja)
|
2017-10-04 |
2023-06-06 |
セルジーン コーポレイション |
シス-4-[2-{[(3s,4r)-3-フルオロオキサン-4-イル]アミノ}-8-(2,4,6-トリクロロアニリノ)-9h-プリン-9-イル]-1-メチルシクロヘキサン-1-カルボキサミドの組成物及び使用方法
|
KR102619071B1
(ko)
*
|
2017-10-11 |
2023-12-27 |
엘랑코 유에스 인코포레이티드 |
돼지 g-csf 변이체 및 그 용도
|
KR20200104291A
(ko)
|
2017-11-06 |
2020-09-03 |
랩트 테라퓨틱스, 인크. |
항암제
|
US11020476B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
BR112020014525A2
(pt)
|
2018-01-19 |
2020-12-08 |
Janssen Pharmaceuticals, Inc. |
Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
WO2020234742A1
(en)
|
2019-05-20 |
2020-11-26 |
Lupin Limited |
Granulocyte colony stimulating factor purification
|
EP4168414A1
(de)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2024064646A1
(en)
|
2022-09-20 |
2024-03-28 |
Celgene Corporation |
Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
|